Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 362–363 (2008)Cite this article

Di Bisceglie AM et al. (2007) Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 14: 721–729

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wohnsland A et al. (2007) Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20: 23–38

    Article  CAS  Google Scholar 

  2. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  CAS  Google Scholar 

  3. Mihm U et al. (2006) Predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 23: 1043–1054

    Article  CAS  Google Scholar 

  4. Schering-Plough reports top-line results of the IDEAL study [http://www.schering-plough.com/schering_plough/news/release.jsp? releaseID=1096126] (accessed online 03 April 2008)

  5. Berg T et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086–1097

    Article  CAS  Google Scholar 

  6. Harrison SA (2007) Small molecule and novel treatments for chronic hepatitis C virus infection. Am J Gastroenterol 102: 2332–2338

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. E Herrmann is a Professor in the Department of Internal Medicine at Saarland University, Homburg, Frankfurt, Germany.,

    Eva Herrmann

  2. S Zeuzem is Professor of Medicine and Head of the Department of Internal Medicine I at the JW Goethe-University Hospital, Frankfurt, Germany.,

    Stefan Zeuzem

Authors
  1. Eva Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Herrmann.

Ethics declarations

Competing interests

S Zeuzem is a Consultant and Speaker and has received grant/research support from Roche and Schering Plough. E Herrmann declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrmann, E., Zeuzem, S. Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection?. Nat Rev Gastroenterol Hepatol 5, 362–363 (2008). https://doi.org/10.1038/ncpgasthep1155

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1155

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing